Clinical trials: Diabetes Type II
Type 2 Diabetes Mellitus
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)
This study will compare the benefits of exenatide once weekly treatment to those achieved by the approved antidiabetic therapies sitagliptin and pioglitazone in subjects whose type 2 diabetes is managed with metformin therapy…
- Trial name
- NCT00637273
- Testing
- exenatide once weekly, sitagliptin, pioglitazone
- Where
- 62 sites in United States, India and 1 more
- Volunteers
- 514 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
- Trial name
- NCT01923389
- Testing
- 100 mg PF-05231023
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
The purpose of this study is to assess the hypothesis that treatment with study medication (omarigliptin; MK-3102) provides greater reduction in A1C Hemoglobin (a marker of diabetic severity) compared with placebo, after 12 weeks…
- Trial name
- NCT01217073
- Testing
- Omarigliptin, Pioglitazone, Metformin
- Volunteers
- 685 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)
The purpose of this study is to evaluate the efficacy and safety of sitagliptin and MK0431A in comparison to a commonly used medication in patients with type 2 diabetes.
- Trial name
- NCT00541450
- Testing
- Comparator: sitagliptin phosphate (sitagliptin), sitagliptin phosphate (+) metformin hydrochloride, Comparator: pioglitazone
- Volunteers
- 492 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2, Pre-diabetes
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans
The rationale for the proposed research is that elucidating changes in localized diacylglycerol (DAG) and sphingolipid species that predict insulin sensitivity will reveal specific localized lipids to target in therapeutics for…
- Conditions
- Diabetes Mellitus, Type 2, Pre-diabetes, Obesity
- Trial name
- NCT03077360
- Testing
- Lifestyle
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Diabetes, Diabetes Mellitus, Type 2
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes.
- Trial name
- LEAD-3 (NCT00294723)
- Testing
- liraglutide, glimepiride
- Where
- 117 sites in United States, Mexico and 1 more
- Volunteers
- 746 people
- Sponsor
- Novo Nordisk A/S
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
This study is a Phase II, placebo-controlled, double-blind, randomized trial in 480 participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (for example, diabetes and familial…
- Conditions
- Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
- Trial name
- ORION-1 (NCT02597127)
- Testing
- ALN-PCSSC, Normal Saline
- Where
- 54 sites in United States, Canada and 3 more
- Volunteers
- 501 people
- Sponsor
- The Medicines Company
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus
The primary purpose of this Study is to help answer the following research question(s). How does LY2189265 affect gastric emptying (the speed at which food and drink leaves the stomach) in patients with Type 2 diabetes? How does…
- Trial name
- NCT01215968
- Testing
- LY2189265
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes
Assess the safety and toleration of CP-464,005 and Inhaler following 1-year (52 week) administration to Type 1 and Type 2 diabetes patients (non-smokers)
- Trial name
- NCT00527397
- Testing
- CP-464,005
- Where
- 10 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Pfizer
Obesity, Overweight
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- ATTAIN-2 (NCT05872620)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 1,613 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Treatment of Diabetes After Gastric Bypass With Sitagliptin
The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.
- Trial name
- LAF33 (NCT01512797)
- Testing
- Sitagliptin phosphate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Blandine Laferrere
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use
The purpose of this study is to demonstrate the performance of the Enlite Sensor over an entire calibration and wear period of 146 hours (6 days) when inserted in the abdomen and buttock and used with the Revel 2.0 Pumps in…
- Trial name
- NCT01464346
- Testing
- Enlite Sensor
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2
A Study of the Effect of LY2189265 on Two Blood Pressure Drugs
The purpose of this study is twofold: 1. To evaluate the effect of LY2189265 on how the body absorbs a blood pressure lowering drug (lisinopril) in participants with high blood pressure who are currently taking lisinopril. 2.
- Trial name
- NCT01324388
- Testing
- LY2189265, Metoprolol, Lisinopril
- Where
- 3 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Chronic Kidney Disease
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.
- Trial name
- REMODEL (NCT04865770)
- Testing
- Semaglutide
- Where
- 49 sites in United States, Canada and 6 more
- Volunteers
- 106 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Hypertension
18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
To determine if olmesartan plus amlodipine combination therapy alone and with hydrochlorothiazide will be safe and effective to reduce high blood pressure in hypertensive, type 2 diabetic subjects.
- Trial name
- NCT00654745
- Testing
- Amlodipine, amlodipine / olmesartan medoxomil combination, Hydrochlorothiazide
- Where
- 21 sites in United States
- Volunteers
- 207 people
- Sponsor
- Daiichi Sankyo
Diabetic Retinopathy
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
- Trial name
- NCT00604383
- Testing
- ruboxistaurin
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Chromaderm, Inc.
Type 2 Diabetes Mellitus
Impact of Structured Physical Activity Education Delivery in Patients With Type 2 Diabetes Mellitus
The objective of this study is to assess whether a structured exercise program compared to routine recommendation for exercise has any positive impact on disease outcome in patients with type 2 diabetes.
- Trial name
- NCT02093702
- Testing
- Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach, Unstructured Physical Activity and Exercise Education
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Royal Victoria Hospital, Canada
Type 2 Diabetes Mellitus
(R33 Phase) DELISH Study: Diabetes Education to Lower Insulin, Sugars, and Hunger
The investigators plan an R33 phase trial in which 120 persons with type 2 diabetes (T2DM) will be randomized (using a 1:1 ratio) to education alone (Ed) on following a carbohydrate restricted diet for T2DM, or this same…
- Trial name
- DELISH R33 (NCT03837405)
- Testing
- Carbohydrate-restricted diet, Mindfuless
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of California, San Francisco
Type 2 Diabetes Mellitus
A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator
This is a 24 week study comparing the efficacy of four dose levels of INT131 besylate with pioglitazone HCl in patients with type 2 diabetes.
- Trial name
- NCT00631007
- Testing
- INT131 besylate, Pioglitazone HCl
- Where
- 66 sites in United States, Mexico
- Volunteers
- 367 people
- Sponsor
- InteKrin Therapeutics, Inc.
Diabetes Mellitus, Type 2, Cancer
Epidemiologic Study Of Diabetes And Cancer Risk
The purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes along with the assessment…
- Trial name
- NCT02958995
- Testing
- No Intervention
- Volunteers
- 2,738,161 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.